Comparative transcriptome analysis of gene profiles altered among new ceramide analogs and ABC294640 treated PEL cell lines. (A) The Human HT-12 v4 Expression BeadChip (Illumina) was used to investigate the transcriptome change between ceramide analogs (315 or 403) and vehicle-treated BCBL-1 and BCP-1 cells. The intersection analysis of significantly altered genes (expression change ≥ twofold; P < .05) was conducted using Illumina GenomeStudio Software. (B-C) The enrichment analysis of gene profile (common and unique) altered by ceramide analogs treatment was conducted using the Pathway Maps Module of MetaCore Software (Thompson Reuters). (D) The intersection analysis of significantly altered genes (expression change ≥ twofold; P < .05) was conducted as described above. (E-F) Heat map and enrichment analysis of genes commonly altered in new ceramide analogs and ABC294640 (ABC) treated PEL cell lines. IL-2, interleukin-2; MIF, macrophage migration inhibitory factor; NFG, nerve growth factor; PKR, protein kinase R; PPAR, peroxisome proliferator-activated receptors; RAR, retinoic acid receptor; SLE, systemic lupus erythematosus; VDR, vitamin D receptor.